Stoke Therapeutics Files 8-K
Ticker: STOK · Form: 8-K · Filed: Dec 5, 2025 · CIK: 1623526
| Field | Detail |
|---|---|
| Company | Stoke Therapeutics, Inc. (STOK) |
| Form Type | 8-K |
| Filed Date | Dec 5, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing, corporate-update
TL;DR
Stoke Therapeutics filed an 8-K on 12/5/25 covering Reg FD, other events, and financials.
AI Summary
Stoke Therapeutics, Inc. filed an 8-K on December 5, 2025, reporting on various events. The filing includes information related to Regulation FD disclosures, other events, and financial statements and exhibits. The company, incorporated in Delaware, is located at 45 Wiggins Avenue, Bedford, Massachusetts.
Why It Matters
This 8-K filing provides updates on regulatory disclosures and other corporate events for Stoke Therapeutics, Inc., which is important for investors to monitor company activities.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting standard corporate information and does not appear to contain significant new risks.
Key Numbers
- 001-38938 — SEC File Number (Stoke Therapeutics' SEC filing identifier)
- 47-1144582 — IRS Employer Identification No. (Stoke Therapeutics' tax identification number)
Key Players & Entities
- Stoke Therapeutics, Inc. (company) — Registrant
- December 5, 2025 (date) — Date of earliest event reported
- 45 Wiggins Ave, Bedford, Massachusetts 01730 (location) — Principal Executive Offices
- ASOthera Pharmaceuticals, Inc. (company) — Former Company Name
FAQ
What specific events are being disclosed under Regulation FD?
The filing indicates a Regulation FD Disclosure but does not detail the specific information released under this regulation within the provided text.
What are the 'Other Events' being reported by Stoke Therapeutics?
The filing mentions 'Other Events' as an item information but does not specify the nature of these events in the provided text.
What financial statements or exhibits are included with this 8-K filing?
The filing lists 'Financial Statements and Exhibits' as an item information, but the specific contents are not detailed in the provided text.
When was Stoke Therapeutics, Inc. formerly known as ASOthera Pharmaceuticals, Inc.?
The date of the name change from ASOthera Pharmaceuticals, Inc. to Stoke Therapeutics, Inc. was October 28, 2014.
What is the primary business of Stoke Therapeutics, Inc. according to its SIC code?
Stoke Therapeutics, Inc. is classified under SIC code 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 1,020 words · 4 min read · ~3 pages · Grade level 14.3 · Accepted 2025-12-05 09:05:11
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share STOK Nasdaq Glo
Filing Documents
- d272524d8k.htm (8-K) — 39KB
- d272524dex991.htm (EX-99.1) — 39KB
- 0001193125-25-308781.txt ( ) — 201KB
- stok-20251205.xsd (EX-101.SCH) — 3KB
- stok-20251205_lab.xml (EX-101.LAB) — 17KB
- stok-20251205_pre.xml (EX-101.PRE) — 11KB
- d272524d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release dated December 5, 2025 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. STOKE THERAPEUTICS, INC. Date: December 5, 2025 By: /s/ Thomas E. Leggett Thomas E. Leggett Chief Financial Officer